|
Published by: SMI Publishing, Ltd
Published: Sep. 20, 2006
Table of Contents
- Day 1
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Eric Tomlinson, President & Chief Executive Officer, Altea Therapeutics.
- 9.10 KEYNOTE ADDRESS
- Improving therapeutics with novel drug delivery
- An overview of the drug delivery industry
- Delivering old drugs in new ways
- Targeted drug delivery
- Novel protein delivery systems
- Dr Eric Tomlinson, President & Chief Executive Officer, Altea Therapeutics.
- 9.50 OVERCOMING SOLUBILITY ISSUES IN PARENTERAL DRUG DELIVERY
- The unmet needs and challenges
- Lipid systems
- Novel non-lipid solubilisers
- Nanoparticulate systems
- Prodrug approach
- Dr Luk Chiu Li, Director, Global Drug Delivery, Abbott Laboratories.
- 10.30 Morning Coffee
- 11.00 NOVEL MUCOADHESIVE POLYMERS
- Topical drug delivery systems
- An overview of the need for novel muco/bioadhesive formulations
- New in vitro models of adhesion assessment
- Antibacterial effects of barrier-enhancing polymers
- Polymer-conjugated cargoes for drug delivery - case studies
- Dr David Brayden, Chairman , United Kingdon-Ireland Controlled Release Society (UKICRS) .
- 11.40 ORAL DOSAGE FORMS
- Novel technologies and considerations
- Traditional and orally disintegrating tablets
- The effect of microenviromental pH on stability and performance
- Solid state chemical and/or physical stability, dissolution and or release profiles
- Case studies
- Dr Joerg Rosenberg, Associate Director, Pharmaceutical Development, Abbott GmbH & Co KG.
- 12.10 Networking Lunch
- 1.50 ASSESSMENT OF ORAL DELIVERY OPTIONS
- Defining NCE oral delivery options within Phase I
- Key factors influencing absorption and bioavailability
- Oral delivery strategies to overcome suboptimal pharmacokinetics
- Strategies for assessing key factors within Phase I
- Flexible clinical protocols to define NCE "developability"
- Case studies involving molecules with complex oral biopharmaceutical properties
- Mr Lloyd Stevens, Business Support Manager, Pharmaceutical Profiles.
- 2.30 PULMONARY DRUG DELIVERY
- Targeted treatment through the lungs
- An overview of non-invasive pulmonary delivery
- In vivo/in vitro aerosols
- Improving the prediction of deposition/absorption
- Case studies - a focus on insulin
- Dr Sheldon Schaffer, Head, Buisness Development, Epic Therapeutics (A subsidiary of Baxter Healthcare).
- 3.10 Afternoon Tea
- 3.40 PROTEIN DELIVERY DEVICES
- The pulmonary delivery of powder and liquid drugs
- Types of devices
- Formulation characteristics: pros and cons
- Selection criteria and how to approach it
- Dr Ola Nerbrink, Principal Scientist, Device Chemistry & Biology, Novo Nordisk A / S.
- 4.20 TRANSDERMAL DRUG DELIVERY
- Overcoming physical barriers of the skin
- Transdermal market trends
- Advantages of transdermal drug delivery
- Physical barriers to skin permeation
- Development of passive transdermal systems
- Active transdermal systems and emerging technology
- Dr Sarah Dexter, Senior Scientist, 3M.
- 5.00 Chairman’s Closing Remarks and Close of Day One
- Day 2
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr S. Moein Moghimi, Senior Lecturer & Head Molecular Targeting & Polym, University of Brighton.
- 9.10 ADVANCES IN TUMOUR TARGETED DRUG DELIVERY SYSTEMS
- Principles and advances
- Pathophysiological principles and physiochemical aspects of delivery systems
- Tumour blood flow and barriers to extravasation
- Pseudoallergic responses associated with delivery systems
- Applying technological advances in chemistry and engineering
- Future platforms
- Dr S. Moein Moghimi, Senior Lecturer & Head Molecular Targeting & Polym, University of Brighton.
- 9.50 LONG-ACTING PARENTERALS
- Injectable microparticles and injectable solid implants
- Delivery of small molecules, peptides, and proteins for days, weeks, and months with a single administration
- Examples of long-acting parenteral products on the market and in the clinic
- Science and technology behind long-acting parenterals
- Designing, developing and manufacturing injectable microparticles and injectable solid implants
- Disclosure of a new injectable solid implant process technology that decreases implant dimensions and increases drug content
- Dr Tom Tice, Executive Vice President & Chief Scientific Officer, Brookwood Pharmaceuticals.
- 10.30 Morning Coffee
- 11.00 GMP-PRODUCTION OF LIPOSOMAL VACCINES AND THERAPEUTICS
- From the laboratory to the industrial scale
- Liposomes - a drug delivery system or a vaccine carrier?
- Presentation of a novel liposome technology platform
- Advantages: scalable, reproducible and aseptic production systems; the wide variety of liposomal drugs/vaccines
- Liposome drug and vaccine examples: a look at proteins, peptides and nucleic acids
- Preclinical and clinical data
- Dr Andreas Wagner, Head, Liposome Technology, Polymun Scientific GmbH.
- 11.40 NANOPARTICULATE SYSTEMS FOR PROTEIN DELIVERY
- Self-assembled polyaminoacids for protein controlled release
- Polymer design
- Protein association, dissociation and stability
- Clinical experience
- Dr You-Ping Chan, Director, Chemistry & Analytical Research, Flamel Technologies S.A..
- 12.20 Networking Lunch
- 1.50 siRNA GENE INHIBITION THERAPEUTICS
- Tissue targeted, self assembly nanoparticle systems
- A drug delivery system to create drug agents, combination drugs and multi-targeted cocktails
- An overview of research programmes
- Oncology
- Ocular diseases
- Respiratory viral infections
- Transplantation
- A case study in anti-angiogenesis therapy in oncology
- Dr Martin Woodle, President & Chief Scientific Officer, Intradigm Corporation.
- 3.10 Afternoon Tea
- 3.40 WHEN DEVICES BECOME MORE THAN JUST FOR DELIVERY
- Real world case studies
- Defending your brand with drug delivery technology - what can drug delivery technology do for a brand?
- Extracting greater value with mature brands
- Improved formulary and access in managed care plans in the US
- What is important to patients and providers?
- Mr David Stern, Executive Vice President, Metabolic & Endocrinology, Serono Inc.
- 4.20 COMBINATION PRODUCTS
- A new approach to drug delivery
- Combination products - what are they?
- Advantages of this paradigm
- Regulatory issues 101 - pathway to approval
- Regulatory issues 102 - post-approval challenges
- Dr Mason Diamond, Vice President, Clinical & Regulatory Affairs, TyRx Pharma.
- 5.00 Chairman’s Closing Remarks and Close of Conference
AbstractIn recent years, the drug delivery industry has focused on the development of established drugs coming off patent. With an ever-increasing competition in the market, drug delivery companies must become more involved in the earlier stages of drug development in addition to the discovery and research of innovative new materials and technologies.
SMi’s Drug Delivery Global Summit is designed to bring together key industry leaders from the pharmaceutical, biotechnology and drug delivery fields. Providing expert opinion, the conference offers the latest discoveries and trends in transdermal, opthalmic, oral, nasal and pulmoanry delivery, nanotechnology, drug delivery design and formulation strategies. This event also offers advice on the business and management side of developing a new delivery device and successfully brining it to market.
Hear International case studies and expert perspectives from leaders in the field, including:
- David Stern, Executive Vice President, Metabolic & Endocrinology, Serono
- Dr Eric Tomlinson, President & Chief Executive Officer, Altea Therapeutics
- Dr Martin Woodle, President & Chief Scientific Officer, Intradigm Corporation
- Steven White, Senior Director, Product Development, Epic Therapeutics, Baxter Healthcare
- Dr Tom Tice, Executive Vice President & Chief Scientific Officer, Brookwood Pharmaceuticals
- Dr Mason Diamond, Vice President, Clinical & Regulatory Affairs, TyRx Pharma
- Dr Luk Chui Li, Director, Global Drug Delivery, Abbott
- Dr Jorg Rosenberg, Associate Director, Pharmaceutical Development, SOLIQS, Abbott
- Dr Ola Nerbrink, Principal Scientist, Device Chemistry & Biology, Novo Nordisk
- Dr David Brayden, Chairman, UK-Ireland Chapter, Controlled Release Society
Key issues that will be addressed at the conference include:
- Novel drug delivery systems: Hear about the latest developments in drug delivery design and how to comply with Good Manufacturing Practice
- Nanotechnology: Discover how advances in nanotechnology can advance the drug delivery industry through novel design and application
- Targeted drug delivery: Consider how targeting drug action can revolutionise medical treatment and understand the latest developments that can make this a reality
- Controlled Release: Appreciate the science and technology behind long-acting parenterals and the design, development and manufacturing considerations for implants and injectable formulations
- Challenges in drug solubility and adsorption barriers: Recognise the pitfalls associated with hydrophobic drugs, their delivery and action
- Networking opportunities: Meet the key industry leaders, make valuable contacts and learn from their experience and expertise
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
